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NF-κB Regulation of c-FLIP Promotes TNFα-Mediated
RAF Inhibitor Resistance in Melanoma
Yongping Shao1,2, Kaitlyn Le3, Hanyin Cheng3 and Andrew E. Aplin3,4
Targeted inhibitors elicit heterogeneous clinical responses in genetically stratiﬁed groups of patients. Although
most studies focus on tumor intrinsic properties, factors in the tumor microenvironment were recently found to
modulate the response to inhibitors. Here, we show that in cutaneous BRAF V600E melanoma, the cytokine
tumor necrosis factor-α (TNFα) blocks RAF inhibitor–induced apoptosis via activation of NF-κB. Several NF-κB-
dependent factors are upregulated following TNFα and RAF inhibitor treatment. Of these factors, we show that
death receptor inhibitor cellular caspase 8 (FLICE)-like inhibitory protein (c-FLIP) is required for TNFα-induced
protection against RAF inhibitor. Overexpression of c-FLIP_S or c-FLIP_L isoform decreased RAF inhibitor–
induced apoptosis in the absence of TNFα. Importantly, targeting NF-κB enhances response to RAF inhibitor
in vitro and in vivo. Together, our results show mechanistic evidence for cytokine-mediated resistance to RAF
inhibitor and provide a preclinical rationale for the strategy of cotargeting the RAF/MEK/ERK1/2 pathway and the
TNFα/NF-κB axis to treat mutant BRAF melanomas.
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INTRODUCTION
Targeted inhibitors, such as vemurafenib and dabrafenib,
elicit strong but heterogeneous effects in mutant BRAF V600E
cutaneous melanoma patients (Flaherty et al., 2010; Hauschild
et al., 2012; Long et al., 2012; Sosman et al., 2012). However,
∼50% of patients do not achieve a partial or complete
response. Furthermore, many patients who achieve an
objective response ultimately develop acquired resistance
(Hartsough et al., 2014). Heterogeneous modes of resistance
have been identiﬁed in patient samples with reactivation of
extracellular signal–regulated kinase 1/2 (ERK1/2) signaling
being a frequent mechanism. Simultaneously targeting multiple
steps in the RAF/MEK/ERK1/2 pathway is more efﬁcacious than
single-agent therapy (Flaherty et al., 2012); however, resistant
tumors still emerge. These ﬁndings indicate that the efﬁcacy of
single pathway targeting is limited, and strategies need to be
developed to cotarget alternative pathways.
The tumor microenvironment modulates the response to
targeted therapies. Growth factors including hepatocyte growth
factor and neuregulin 1 provide protective signals counter-
acting the effects of vemurafenib (Straussman et al., 2012;
Wilson et al., 2012; Abel et al., 2013). Accordingly, cotargeting
the corresponding receptor tyrosine kinase pathway and the
RAF/MEK/ERK pathway elicited better outcome than single
pathway targeting (Lito et al., 2012; Straussman et al., 2012;
Wilson et al., 2012; Abel et al., 2013). However, because of
the complex composition of the tumor microenvironment,
additional compensatory pathways will likely modulate the
response to RAF inhibitors and will need to be targeted to
maximize the effects of RAF and MEK inhibitors in melanoma.
Advanced-stage melanoma cells often have constitutive IκB
kinase and NF-κB activity (Meyskens et al., 1999; Yang and
Richmond, 2001). NF-κB is a family of protein complexes that
controls the transcription of genes involved in inﬂammatory
response and cell survival (Karin and Lin, 2002; Lawrence,
2009). Antiapoptotic targets of NF-κB include Bcl-2 (Catz and
Johnson, 2001) and Bcl-xl (Chen et al., 2000), the inhibitor of
apoptosis (IAP) family proteins (c-IAP1 (Stehlik et al., 1998a),
c-IAP2 (Stehlik et al., 1998a), XIAP (Stehlik et al., 1998b),
survivin (Kawakami et al., 2005)), and death receptor inhibitor
cellular caspase-8 (FLICE)-like inhibitory protein (c-FLIP)
(Kreuz et al., 2001), and therefore NF-κB is implicated in
radiation- and chemo-resistance in many cancers (Wang
et al., 1999; Magne et al., 2006).
In the tumor microenvironment, tumor-associated macro-
phages (TAMs) produce cytokines such as tumor necrosis
factor-α (TNFα) and IL-1β, which are potent inducers of the
NF-κB pathway. Studies have shown that TAM inﬁltration
is associated with melanoma stage and angiogenesis
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(Torisu et al., 2000) and may serve as a prognostic marker for
AJCC (American Joint Committee on Cancer) stage I/II
melanoma (Jensen et al., 2009). Furthermore, targeting the
tumor NF-κB pathway or blocking TNFα signaling in TAMs
sensitized melanoma cells to chemotherapy or radiation
therapy (Amiri et al., 2004; Meng et al., 2010). TNFα also
blocks apoptosis induced by MEK inhibitor or BRAF depletion
in mutant BRAF melanoma cells, although the underlying
mechanism remains unclear (Gray-Schopfer et al., 2007).
Here, we tested the role of the NF-κB pathway in the
responses of mutant BRAF melanoma cells to RAF inhibition.
We show that activation of the NF-κB pathway by TNFα
protects melanoma cells against the RAF inhibitor via
upregulation of the antiapoptotic protein c-FLIP. Importantly,
targeting the NF-κB pathway sensitized melanoma cells to the
RAF inhibitor in vitro and in vivo. Our data provide the
rationale for cotargeting the RAF/MEK/ERK and NF-κB
pathways to treat mutant BRAF melanoma.
RESULTS
The NF-κB agonist, TNFα, protects melanoma cells from RAF
inhibitor–induced apoptosis
To test the role of the NF-κB pathway in the response of
melanoma cells to RAF inhibitor, we treated three mutant
BRAF melanoma cells with TNFα and examined their
response to PLX4720, the tool compound for vemurafenib
(Tsai et al., 2008). Treatment with TNFα signiﬁcantly
enhanced NF-κB reporter activity in both untreated and RAF
inhibitor–treated cells, although activation was slightly lower
in the presence of PLX4720 (Figure 1a). Consistent with
previous observations (Shao and Aplin, 2010), PLX4720
elicited strong cytotoxic effects in BRAF V600E melanoma
cells (Figure 1b and c and Supplementary Figure S1 online).
TNFα treatment alone slightly increased the basal level of cell
death in A375 but not M238 and M229 cells. Importantly,
TNFα strongly protected multiple BRAF V600E melanoma
cells against the cytotoxic effect of PLX4720 but had little
impact on cell cycle progression (Figure 1b and c and
Supplementary Figure S1 online). TNFα was also protective
against the RAF plus MEK inhibitor combination but did not
reduce death induced by etoposide (Supplementary Figure
S1c online). Cleaved caspase 3 was detected 24–48 hours
following PLX4720 treatment and was strongly inhibited by
TNFα stimulation (Figure 1c). Furthermore, activation of both
intrinsic (caspase 9) and extrinsic (caspase 8) apoptosis
pathways was detected following PLX4720 treatment and
was inhibited by TNFα (Figure 1c). Cleavage of caspases 3
and 9 was ﬁrst detected at ~ 18 hours following PLX4720
treatment, whereas caspase 8 cleavage showed a delay of
2–4 hours (Supplementary Figure S2a online), suggesting
that caspase 9 activation is an upstream event in RAF
inhibitor–induced apoptosis. Interestingly, caspase 8 deple-
tion reduced cleavage of caspases 3 and 9 (Supplementary
Figure S2b online), suggesting cross-talk between these
caspases. Together, these results show that TNFα protects
melanoma cells from RAF inhibitor–induced apoptosis and
counteracts the activation of caspases 3, 8, and 9.
NF-κB signaling is required for TNFα-mediated protection from
RAF inhibitor–induced apoptosis
Next, we tested the requirement for NF-κB in TNFα-mediated
protection. We selectively depleted the NF-κB components,
p50 and p65, alone and in combination, as conﬁrmed by
western blot (Figure 2a). Depletion of p50 and p65
individually or in combination completely reversed the
TNFα-mediated protection against the RAF inhibitor cytotoxi-
city (Figure 2b–d). Knockdown of NF-κB components also
sensitized melanoma cells to TNFα treatment, indicating that
NF-κB may confer natural resistance of melanoma cells to
TNFα-induced apoptosis. In the case of A375 cells, TNFα
treatment in p65 and p65 plus p50 knockdowns further
augmented the apoptotic effect of PLX4720 (Figure 2b). These
data indicate that TNFα-mediated protection against RAF
inhibitor requires NF-κB. In contrast, NF-κB p65 and p50
knockdowns had little impact on the sensitivity of melanoma
cells to nontargeted chemotherapeutics such as etoposide and
cisplatin (Supplementary Figure S3a and b online).
c-IAP2 and c-FLIP are upregulated upon TNFα and PLX4720
treatment in an NF-κB-dependent manner
To identify the downstream effectors of NF-κB that may
account for the protection against PLX4720, we analyzed the
expression of NF-κB target proteins known to regulate
apoptosis. We focused on differences in target expression in
cells treated with PLX4720 alone and with a combination of
PLX4720 and TNFα. Upregulation of the BH3-only proteins,
Bim-EL and Bmf, and downregulation of the Bcl-2 family
protein, Mcl-1, by PLX4720 (Boisvert-Adamo et al., 2009; Shao
and Aplin, 2010) were not signiﬁcantly altered by TNFα
(Supplementary Figure S4a online). Furthermore, no apparent
TNFα-regulated differences were observed in other Bcl-2
family proteins and most IAP family proteins (XIAP, survivin,
livin, and c-IAP1) (Supplementary Figure S4a online). In
contrast, two antiapoptotic proteins, c-IAP2 and c-FLIP, were
upregulated by TNFα and PLX4720 when compared with
PLX4720 alone (Figure 3a).
c-IAP2 was upregulated by TNFα alone in A375 and M238
cells and cotreatment with PLX4720 weakened this upregula-
tion, possibly because of a decreased NF-κB activity upon RAF
inhibitor treatment (Figure 3a). The mRNA levels of c-IAP2 were
regulated in a similar pattern (Figure 3b). Regulation of c-FLIP
was more complex. TNFα alone induced c-FLIP protein
expression in M238 cells, whereas PLX4720 treatment alone
slightly enhanced c-FLIP expression in A375 cells (Figure 3a
and Supplementary Figure S5 online). Multiple forms of c-FLIP
provide protection from death receptor–mediated apoptosis
(Scafﬁdi et al., 1999; Krueger et al., 2001; Golks et al., 2005),
and we detected upregulation of the long isoform, c-FLIP_L, in
our studies. The mRNA levels of c-FLIP were upregulated by
TNFα alone or TNFα with PLX4720 in A375 and M238 cells
(Figure 3b). Despite this complexity, a consistent observation
was that c-FLIP expression was upregulated in the combined
TNFα- and PLX4720-treated cells versus PLX4720-alone-treated
cells (Figure 3a, and quantitated in Supplementary Figure S5
online). This observation was also conﬁrmed in M229 cells
(Supplementary Figure S4b and c online).
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To conﬁrm that the regulation of c-IAP2 and c-FLIP by
TNFα is dependent on NF-κB, we analyzed their expression in
A375 and M238 cells depleted of NF-κB subunits (Figure 3c).
Consistent with our data, in control small interfering RNA
(siRNA)–treated A375 and M238 cells, PLX4720 and TNFα
combination treatment enhanced the expression of c-IAP2
and c-FLIP when compared with PLX4720-alone treatment.
However, the upregulation of both proteins was blunted in
p50- or p65-depleted cells, indicating that the regulation of
c-IAP2 and c-FLIP is NF-κB dependent.
c-FLIP but not c-IAP2 is required for TNFα-induced protection
against PLX4720
As both c-IAP2 and c-FLIP have antiapoptotic roles (Liston
et al., 1996; Safa and Pollok, 2011), we tested individually the
requirement for these two proteins in TNFα-induced
protection against PLX4720. Selective siRNAs effectively
reduced the induction of c-IAP2 (490% and 75%
downregulation in M238 and M229, respectively) and
c-FLIP (490% and 87% downregulation in M238 and
M229, respectively) by TNFα and PLX4720 (Figure 4a).
Surprisingly, cells depleted of c-IAP2 were still protected by
TNFα against PLX4720-induced apoptosis to a level compar-
able to control-transfected cells (Figure 4b). In contrast,
depletion of c-FLIP completely restored cell death in the
presence of TNFα and PLX4720 (Figure 4b and
Supplementary Figure S6 online). Similarly, the cleavage of
caspases 3, 8, and 9 in the TNFα plus PLX4720 treatment
samples was recovered, at least partially, to the level of
PLX4720 treatment alone samples in c-FLIP-depleted but not
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Figure 1. Tumor necrosis factor-α (TNFα) protects melanoma cells from RAF inhibitor–induced apoptosis. (a) Luciferase assays were performed as described in
the Materials and Methods. Cells were treated with ± 50 ngml−1 TNFα and ±5 μM PLX4720 for 24 hours. Average relative luciferase activities from three
experiments are shown. Error bars represent SD. **Po0.01. (b) Cells were treated with ±50 ngml−1 TNFα and either ± 10 μM PLX4720 for 72 hours (A375) or
±5 μM PLX4720 for 48 hours (M238, M229). Cells stained with propidium iodide (PI) for cell cycle analysis. Average percentages of sub-G1 populations from
three experiments are quantiﬁed. *Po0.05; **Po0.01; ***Po0.001. (c) A375, M238, and M229 cells were treated with ±50 ngml−1 TNFα and ±5 μM PLX4720
for 8–72 hours. Cells lysates were analyzed by western blotting. Arrows indicate full-length or cleaved (Cl.) products of caspases. Relative levels of cleaved
caspases are indicated below the corresponding blots. pERK1/2, phosphorylated extracellular signal–regulated kinase 1/2.
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c-IAP2-depleted M238 and M229 cells (Figure 4a). c-FLIP
depletion had no impact on cell death induced by ERK1/2
pathway-independent drugs such as etoposide and cisplatin
(Supplementary Figure S3 online). These results suggest that
c-FLIP but not c-IAP2 is required for TNFα-mediated protec-
tion against RAF inhibitor.
Overexpression of c-FLIP protects melanoma cells against
PLX4720-induced apoptosis
To further test the role of c-FLIP as the prosurvival effector
downstream of NF-κB, we examined whether c-FLIP was
sufﬁcient to protect against PLX4720-induced apoptosis. We
stably expressed either c-FLIP_S (short isoform), c-FLIP_L
(long isoform), or LacZ (as a control) in A375 cells, as veriﬁed
by western blotting (Figure 5a). We then tested for the
response to PLX4720. PLX4720 treatment led to decreased
expression of transgenes, presumably due to reduced CMV
promoter activity upon ERK1/2 signaling inhibition (Chen and
Stinski, 2002). Consistent with prior results, treatment of RAF
inhibitor induced ∼ 45% cell death in LacZ-expressing A375
cells (Figure 5b). Ectopic expression of c-FLIP_S or c-FLIP_L
decreased cell death to 12% or 16%, respectively. The
reduction in cell death was associated with lower detectable
levels of cleaved caspases 3, 8, and 9 (Figure 5a). To conﬁrm
that the protective role of c-FLIP was not cell line dependent,
we conducted similar experiments in M229 cells and used
another negative control, green ﬂuorescent protein (Figure 5c
and d). The green ﬂuorescent protein–expressing M229 cells
exhibited 48% cell death after RAF inhibitor treatment, and
this was decreased to 34% or 28% following c-FLIP_S or
c-FLIP_L expression, respectively. Therefore, c-FLIP isoforms
are sufﬁcient to protect mutant BRAF melanoma cells from
PLX4720-induced cell death.
Targeting p65 NF-κB enhances the response to PLX4720 in vitro
and in vivo
Prompted by our observations, we hypothesized that targeting
the NF-κB pathway may synergize with the RAF inhibitor,
PLX4720. p65 is a major component of the NF-κB signaling
complex; thus, we generated two 1205Lu cell lines (harboring
doxycycline-inducible short hairpin RNAs (shRNAs) targeting
p65. In the absence of doxycycline, PLX4720 treatment
induced 5–10% cell death after 24 hours and 40–50% after
48 hours in both cell lines in vitro (Figure 6b). Treatment of
doxycycline led to efﬁcient knockdown of p65 and reduction
in c-FLIP expression in both cell lines and signiﬁcantly
increased cell death after 24 and 48 hours of PLX4720
treatment (Figure 6a and b).
We further tested this hypothesis in a mouse xenograft
model using A375 cells expressing either control nontargeting
or p65-speciﬁc shRNAs controlled by doxycycline. A375TR
cells were used for their reproducible tumor-forming ability
in nude mice and efﬁcient doxycycline inducible knock-
downs (Abel et al., 2013). Doxycycline treatment signiﬁ-
cantly decreased p65 expression in A375TR p65 shRNA 2
and 3 cells (Figure 6c). In vivo, p65 shRNA induction
had marginal impact on tumor growth in the absence of
the RAF inhibitor. Treatment with the RAF inhibitor alone
partially inhibited tumor growth, consistent with partial
resistance of this cell line to RAF inhibitor–induced cell death
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Figure 2. Tumor necrosis factor-α (TNFα)–induced protection from RAF inhibitors is mediated by NF-κB. (a) Melanoma cells were transfected with control
(Ctrl), p50, or p65 small interfering RNAs (siRNAs) for 72 hours. Cells lysates analyzed by western blotting. Knockdown efﬁciency was estimated by band intensity
quantitation and shown below the blots. (b–d) Melanoma cells were transfected with indicated siRNAs for 72 hours and treated with ±50 ngml−1 TNFα and
±5 μM PLX4720 for 48 (M229 and M238) or 72 (A375) hours before being harvested for propidium iodide (PI) cell cycle analysis. Average percentage of sub-G1
population from three experiments was plotted for each condition. ERK2, extracellular signal–regulated kinase 2. Error bars represent SD. For statistics, one-way
analysis of variance (ANOVA) analyses followed by the Bonferroni test were performed on TNFα+PLX4720 treatment groups. ***Po0.001.
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(Shao and Aplin, 2010). Remarkably, tumor growth was
further inhibited when RAF inhibitor was combined with p65
depletion (Figure 6d). Analysis of harvested tumors at the end
of the xenograft experiment showed a reduction in p65 with
shRNAs (Supplementary Figure S7 online), although levels
were variable because of the late time point of harvesting (day
28) and the presence of stromal cells. In summary, targeting
the NF-κB pathway enhances the response to RAF inhibitor
in vitro and in vivo.
DISCUSSION
The response in mutant BRAF melanoma patients to RAF
inhibitors is heterogeneous (Hartsough et al., 2014). Although
many forms of acquired resistance involve changes in the
allelic frequency of mutations that reactivate the RAF/MEK/
ERK1/2 pathway, factors in the tumor microenvironment are
important in modulating the primary response to RAF inhibitors
(Straussman et al., 2012; Wilson et al., 2012; Abel et al., 2013).
In this study, we showed that TNFα modulates the apoptotic
response of mutant BRAF melanoma cells to the RAF inhibitor,
PLX4720, in an NF-κB-dependent manner. This work builds on
previous studies showing that TNFα blocks apoptosis in
melanoma cells treated with MEK inhibitors depleted for
BRAF (Gray-Schopfer et al., 2007) and adds TNFα to the list of
factors that provide protection against RAF inhibitor
monotherapy and the RAF/MEK inhibitor combination.
Our results showed that TNFα protects melanoma cells
against the RAF inhibitor–induced apoptosis by upregulation
A375
6 h
–
– –
–
+ +
++ –
– –
–
+ +
++ –
– –
–
+ +
++ –
– –
–
+ +
++PLX4720
TNF-α
c-FLIP
c-IAP2
pERK1/2
Actin
c-FLIP/Actin: 0.2 0.2 0.20.3 0.2 0.5 1.00.3 0.1 0.1 0.10.2 0.2 0.2 1.00.8
24 h
M238
A375
c-IAP2 c-FLIP c-IAP2 c-FLIP
DMSO
PLX4720
PLX4720
+TNF-α
TNF-α
*
*
***
**
* *
**
6 h
siRNA:
TNF-α –
– –
–
+
+ +
+
–
– –
–
+
+ +
+
–
– –
–
+
+ +
+
–
– –
–
+
+ +
+
–
– –
–
+
+ +
+
–
– –
–
+
+ +
+PLX4720
c-FLIP
c-FLIP/Actin: 0.3 0.3 0.3 0.3 0.30.30.20.2 0.2 0.2 0.2 0.2 0.20.5 0.5 0.50.4 0.40.4 0.4 0.4 0.81.0 1.0
c-IAP2
pERK1/2
Actin
24 h 6 h 24 h 6 h 24 h 6 h 24 h
R
el
at
iv
e 
m
R
N
A 
le
ve
l
R
el
at
iv
e 
m
R
N
A 
le
ve
l
M238
A375
Ctrl p50 p65 Ctrl p50 p65
M238
6 h 24 h
0
1
2
3
4
0
1
2
3
4
5
6
0
2
4
6
8
10
0
2
4
6
8
10
12
14
16
18
Figure 3. c-IAP2 (cellular inhibitor of apoptosis 2) and c-FLIP (cellular caspase 8 (FLICE)-like inhibitory protein) are upregulated by tumor necrosis factor-α
(TNFα) and PLX4720 cotreatment. (a) A375 and M238 cells were treated with ± 50 ngml−1 TNFα and ±5 μM PLX4720 for 6 or 24 hours before analysis by
western blotting. Normalized c-FLIP/actin band intensity ratios are shown. pERK1/2, phosphorylated extracellular signal–regulated kinase 1/2. (b) A375 and M238
cells were treated as in a and total RNA isolated and quantitative reverse transcriptase–PCR (qRT-PCR) performed on c-IAP2 and c-FLIP genes. Housekeeping
genes, actin or EEFA1, were internal controls. Average results from three independent experiments are shown. Error bars represent SD. *Po0.05; **Po0.01;
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of c-FLIP. Furthermore, ectopic expression of c-FLIP is
sufﬁcient to decrease RAF inhibitor–induced apoptosis in
the absence of exogenous TNFα. The molecular details of
c-FLIP-mediated protection remain unclear. c-FLIP is gener-
ally implicated in protection against extrinsic apoptosis,
although the long isoform, c-FLIP_L, may either promote or
inhibit apoptosis depending on its expression level (Chang
et al., 2002). In the extrinsic apoptosis pathway, activated
death receptors induce the assembly of death-inducing
signaling complex. The death-inducing signaling complex
recruits the FADD (Fas-associated death domain-containing
protein) that in turn recruits procaspase 8 via its death-effector
domain for self-cleavage and activation. All three c-FLIP
isoforms (c-FLIP_L, c-FLIP_S, and c-FLIP_R) carry two death-
effector domains at the N terminus that enable them to
compete with procaspase 8 for binding to FADD and prevent
apoptosis (Irmler et al., 1997; Rasper et al., 1998). c-FLIP may
contribute to RAF inhibitor resistance by preventing caspase 8
activation induced by RAF inhibitor. Indeed, overexpression
of c-FLIP rescued PLX4720-induced apoptosis with a con-
current reduction in caspase 8 cleavage, as well as cleavage
of caspases 3 and 9 (Figure 5a); knockdown of c-FLIP led to
the recovery of caspase 8 cleavage that was inhibited by
TNFα plus PLX4720 treatment (Figure 4a). In addition,
caspase 8 interference protected melanoma cells against
PLX4720 but not etoposide treatment (Supplementary Figure
S8 online). Although our data implicate the c-FLIP/caspase 8
axis in the protective role of TNFα against the RAF inhibitor, it
is still possible that c-FLIP protects melanoma cells against
PLX4720 through other downstream targets. For example,
c-FLIP may counteract the activation of caspase 10, another
caspase activated upon death-inducing signaling complex
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engagement (Safa and Pollok, 2011). Previous studies have
shown that c-FLIP expression is elevated in melanoma
compared with benign melanocytic lesions (Bullani et al.,
2001), and suppression of c-FLIP expression sensitizes
melanoma cells to death ligand–induced apoptosis
(Geserick et al., 2008). Thus, strategies to decrease c-FLIP
expression may prove efﬁcacious for melanoma.
Consistent with previous studies (Kreuz et al., 2001), we
found in melanoma cells that TNFα upregulated c-FLIP at the
transcriptional level in an NF-κB-dependent manner. The
regulation of c-FLIP may be complex as it is regulated by
several transcription factors (Safa et al., 2008), and
posttranslational regulation may also occur (Chang et al.,
2006). Nevertheless, the c-FLIP protein level was consistently
elevated in PLX4720 and TNFα cotreated cells compared with
cells treated with PLX4720 alone, supporting its protective
role against PLX4720.
Studies on resistance to RAF inhibitors have mainly focused
on the RAF/MEK/ERK and phosphatidylinositol 3 kinase/AKT
pathways. We present a mechanism of resistance and
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possible therapeutic strategies. Importantly, we identiﬁed the
NF-κB pathway as an anti–apoptotic signal in RAF inhibitor–
treated melanoma cells and cotargeting mutant BRAF and the
NF-κB pathway had enhanced antitumor effects in vitro and
in vivo compared with targeting either pathway alone. The NF-
κB pathway is implicated in chemo-/radio-therapy resistance
of many cancers and is readily targetable by various
compounds that target this pathway at different levels.
Bortezomib, a proteasome inhibitor, inhibits the NF-κB path-
way by preventing the degradation of the NF-κB inhibitor, IκB.
The small molecule, BMS-345541, speciﬁcally inhibits the NF-
κB upstream activating kinase, IκB kinase-β (Burke et al.,
2003). Furthermore, NEMO-binding domain peptides block
the interaction between NEMO and the IκB kinase complex
(May et al., 2000). TAMs are a major source of TNFα in the
tumor microenvironment, and TAM inﬁltration into tumors is
enhanced by RAF and MEK inhibitor treatment (Smith et al.,
2014). Targeting TAMs may be a viable alternative to direct
NF-κB intervention, and the clinical efﬁcacy of combined
treatment of macrophage inhibitor PLX3397 and vemurafenib
on BRAF V600E melanoma patients is under investigation.
In summary, our ﬁndings underline the importance of the
tumor microenvironment component, TNFα, to the respon-
siveness of BRAF V600E melanoma cells to RAF inhibitors
and provide a strong rationale for the strategy of cotargeting
the RAF/MEK/ERK1/2 pathway and the TNFα/NF-κB axis to
treat this subset of melanomas.
MATERIALS AND METHODS
Reagents
PLX4720 was provided by Dr Gideon Bollag and Plexxikon (Berkeley,
CA). TNFα was purchased from Sigma-Aldrich (St Louis, MO).
Doxycycline was obtained from Thermo Scientiﬁc (Rockford, IL).
Cell culture
Melanoma cells were cultured as previously described (Shao and
Aplin, 2012; Abel et al., 2013). Cell lines were sequenced at multiple
loci. 1205LuTR and A375TR are sublines with high Tet repressor
expression (Abel et al., 2013).
Western blotting
Western blotting was performed, as previously described (Shao and
Aplin, 2010).
Antibodies against Bcl-xL, phospho-ERK1/2 (Thr202/Tyr204), cas-
pase 8, caspase 9, caspase 3, c-IAP1, cIAP2, XIAP, livin, survivin, p50,
and hemagglutinin (HA) tag were purchased from Cell Signaling
Technology (Beverley, MA). ERK2 and p65 antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). In addition,
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Figure 6. NF-κB targeting enhances responses to PLX4720 in vitro and in vivo. (a) 1205LuTR p65 short hairpin RNA (shRNA) 2 or 3 cells were grown in
±100 ngml−1 doxycycline (Dox) for 3 days and then lysed for western blotting on p65, c-FLIP (cellular caspase 8 (FLICE)-like inhibitory protein), and actin.
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antibodies toward Bcl-2 and Mcl-1 (BD Biosciences, San Jose, CA),
anti-actin (Sigma-Aldrich), Bim (Stressgen, San Diego, CA), Bmf (ENZO
Life Science, Farmingdale, NY), and c-FLIP (Adipogen, San Diego, CA)
were utilized.
Luciferase assay
Melanoma cells were transfected with pNF-κB-luc plasmid (2 μg per
33mm well) using Fugene HD reagent (Promega, Madison, WI). After
24 hours, cells were harvested and subcultured equally into 8 wells.
Next day, 4 wells were treated with ±TNFα and ±PLX4720,
respectively, for another 24 hours and lysed for the luciferase assay
using the Dual-Luciferase Reporter Assay Kit (Promega). The other four
wells were treated in the same manner and lysed for the Bradford
Assay. The luciferase readings were normalized against Bradford Assay
readings accordingly and plotted against each treatment condition.
Quantitative reverse transcriptase–PCR
Total RNA isolation and quantitative reverse transcriptase–PCR were
performed as previously described (Shao and Aplin, 2010). Primer
sequences are provided in the Supplementary Information online.
Propidium iodide staining
Cells were treated with indicated drugs for 24 hours and then washed
in phosphate-buffered saline and ﬁxed in 70% ethanol for 2 hours.
Fixed cells were washed in phosphate-buffered saline, pelleted, and
resuspended in 500 μl propidium iodide staining buffer (phosphate-
buffered saline with 40 μgml− 1 propidium iodide (Sigma-Aldrich),
100 μg ml−1 RNaseA (Thermo Scientiﬁc), and 0.1% Triton X-100).
Cells were stained for 30 minutes at room temperature and analyzed
by ﬂow cytometry on a FACS Calibur. Data were analyzed using
Flowjo software (Three Star, Ashland, OR).
RNA interference
Cells were transfected for 72 hours with 12.5 nM siRNAs and
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA). The siRNAs
for p50 (5′-GCAAUAGCCUGCCAUGUUU-3′), p65 (5′-GGAUUG
AGGAGAAACGUAA-3′), c-IAP2 (5′-UCAAUGAUCUUGUGUUAG
A-3′), c-FLIP (5′-GAUGUGUCCUCAUUAAUUU-3′), and nontarget-
ing siRNA control (5′-UAGCGACUAAACACAUCAA-3′) were pur-
chased from Dharmacon (Lafayette, CO).
Lentiviral complementary DNA constructs
c-FLIP complementary DNA isoforms (HA-c-FLIP-L and HA-c-FLIP-S)
were ampliﬁed from a melanoma complementary DNA pool to
incorporate a HA tag using the KOD hot Start DNA polymerase kit
(EMDMillipore, Billerica, MA). DNA fragments were cloned into pENTR/
D-TOPO vector (Invitrogen), and the resultant entry plasmids were then
recombined with pLentipuro/TO/V5-DEST. Lentivirus were produced in
293FT cells (Shao and Aplin, 2010), and melanoma cells were infected
with lentivirus for 72 hours before selection with puromycin.
Lentiviral shRNA constructs
DNA oligonucleotides were annealed and ligated into pENTR/H1/TO
using the manufacturer’s kit and instructions (Invitrogen). The
sequences are provided in the Supplementary Information online.
The shRNA cassettes were recombined into a destination vector with
puromycin resistance. Lentiviruses were produced and melanoma
cells were transduced, as above.
Animal studies
A375TR cells (1× 106/mouse) were intradermally injected into
female athymic mice (NU/J: Jackson, Bar Harbour, ME) and allowed
to grow for 7 days to reach a palpable tumor size (40–100mm3).
Mice were then exposed to drinking water containing doxycycline
(2 mgml− 1) and 3 days later fed with control chow or PLX4720
chow (90mg kg− 1 PLX4720). The ﬁrst measure of tumor size was
taken (day 0). Subsequently, measurements were taken twice a week
using digital calipers, and tumor volume was determined by the
following formula: volume= (length×width2)× 0.52. Mice were
killed when tumor volume reached 1,000mm3.
Statistical analysis
For in vitro experiments, statistical signiﬁcance of differences
between the results was evaluated using student two-tailed t-test
assuming nonequal variance. For in vivo data, statistical analysis was
conducted using a mixed-effects model and Tukey’s corrected
pairwise comparisons of mean fold change in volume between
treatment groups (SAS statistical software, Cary, NC).
Animal study approval
All animal experiments were approved by the Institutional Animal
Care and Use Committee and conducted in an Association for the
Assessment and Accreditation of Laboratory Animal Care accredited
facility at Thomas Jefferson University (Philadelphia, PA).
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